Deven Choksey is bullish on Glenmark Pharmaceuticals has recommended buy rating on the stock with a target price of Rs 2300 in its research report dated September 02, 2025.

Neutral GSK Pharma; target of Rs 3000: Motilal Oswal

Motilal Oswal recommended Neutral rating on GSK Pharma with a target price of Rs 3000 in its research report dated August 02, 2025.

Reduce GlaxoSmithKline Pharmaceuticals: target of Rs 2,600: ICICI Securities

ICICI Securities recommended reduce rating on GlaxoSmithKline Pharmaceuticals with a target price of Rs 2,600 in its research report dated May 14, 2025.

Neutral GlaxoSmithKline Pharma; target of Rs 1300: Motilal Oswal

Motilal Oswal recommended Neutral rating on GlaxoSmithKline Pharma with a target price of Rs 1300 in its research report dated March 16, 2023.

Pharma: Is the pandemic investment template about to play out?

The return of the flu season in India and the US, and COVID-19 in China sparked more investor interest in the sector.

Neutral GSK Pharma; target of Rs 1570: Motilal Oswal

Motilal Oswal recommended Neutral rating on GSK Pharma with a target price of Rs 1570 in its research report dated May 16, 2022.

Hold GlaxoSmithKline Consumer Healthcare; target of Rs 7972: Prabhudas Lilladher

Prabhudas Lilladher recommended hold rating on GlaxoSmithKline Consumer Healthcare with a target price of Rs 7972 in its research report dated August 05, 2019.

Sell Glaxo SmithKline Pharma; target of Rs 950: Centrum

Centrum is bearish on Glaxo SmithKline Pharma has recommended sell rating on the stock with a target price of Rs 950 in its research report dated October 22, 2018.

Sell GlaxoSmithKline Pharma; target of Rs 1850: Centrum

Centrum is bearish on Glaxo SmithKline Pharma has recommended sell rating on the stock with a target price of Rs 1850 in its research report dated February 03, 2018.

Sell GlaxoSmithKline Pharma; target of Rs 1525: Centrum

Centrum Research is bearish on GlaxoSmithKline Pharma has recommended sell rating on the stock with a target price of Rs 1525 in its research report dated October 25, 2017.

Sell GlaxoSmithKline Pharma; target of Rs 1340: Centrum

Centrum is bearish on GlaxoSmithKline Pharma has recommended sell rating on the stock with a target price of Rs 1340 in its research report dated February 13, 2017.

Hold Glaxosmithkline; target of Rs 5773: Edelweiss

Edelweiss recommended hold rating on Glaxosmithkline with a target price of Rs 5773 in its research report dated February 13, 2017.

Accumulate GSK Consumer; target of Rs 5988: Prabhudas Lilladher

Prabhudas Lilladher has recommended accumulate rating on GSK Consumer with a target price of Rs 5988 in its research report dated November 08, 2016.

Buy GSK Consumer; target of Rs 6765: ICICI Direct

ICICI Direct is bullish on GSK Consumer has recommended buy rating on the stock with a target price of Rs 6765 in its research report dated November 09, 2016.

Hold GSK Consumer; target of Rs 6342: Edelweiss

Edelweiss recommended hold rating on GSK Consumer with a target price of Rs 6342 in its research report dated November 08, 2016.

Accumulate GSK Consumer; target of Rs 6524: Prabhudas Lilladher

Prabhudas Lilladher has recommended accumulate rating on GSK Consumer with a target price of Rs 6524 in its research report dated August 05, 2016.

Sell GlaxoSmithKline; target of Rs 2450: Axis Securities

Axis Securities is bearish on GlaxoSmithKline and has recommended sell rating on the stock with a target price of Rs 2450 in its research report dated February 12, 2016.

Angel Broking neutral on GlaxoSmithKline Pharmaceuticals

Angel Broking has maintained a neutral rating on GlaxoSmithKline Pharmaceuticals, in its May 21, 2015 research report.

Angel Broking neutral on GlaxoSmithKline Pharma

Angel Broking has maintained neutral rating on GlaxoSmithKline Pharma, in its April 28, 2014, research report.

Angel Broking neutral on GlaxoSmithKline Pharmaceuticals

Angel Broking has maintained a neutral rating on GlaxoSmithKline Pharmaceuticals, in its February 19, 2014 research report. The research firm expects the company's net sales to post a 6.0 percent CAGR to Rs 2,853cr and EPS to register a de-growth of 16.2 percent CAGR to Rs 59.4 over CY2013–15E.

Angel Broking neutral on GlaxoSmithKline Pharma

Angel Broking has maintained a neutral rating on GlaxoSmithKline Pharma in its February 20, 2013 research report. The research firm expects company's net sales to post a 13.0% CAGR to Rs 3,319cr and EPS to register a 4.1% CAGR to Rs 86.7 over CY2012–14.

Buy GlaxoSmithKline Pharma; target Rs 2544: Motilal Oswal

Motilal Oswal is bullish on GlaxoSmithKline Pharmaceuticals (GLXO) and has recommended buy rating on the stock with a target price of Rs 2,544 in its research report dated February 21, 2013.

Buy GSK Pharma; target of Rs 2277: Motilal Oswal

Motilal Oswal is bullish on GlaxoSmithKline Pharmaceuticals and has recommended buy rating on the stock with a target of Rs 2277 in its November 27, 2012 research report.

Accumulate GSK Pharma; target of Rs 2104: Dolat Capital

Dolat Capital is bullish on GlaxoSmithKline Pharma and has recommended accumulate rating on the stock with a target of Rs 2104 in its November 21, 2012 research report.